[A20-38] Insulin glargine/lixisenatide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V
Last updated 15.07.2020
Project no.:
A20-38
Commission:
Commission awarded on 03.04.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Digestion, metabolism and hormones
Indication/Intervention:
Type 2 diabetes mellitus
Result of dossier assessment:
Added benefit not proven for either of both research questions
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Accompanying information
Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.
| Project no. | Title | Status |
|---|---|---|
| A18-16 | Insulin glargine/lixisenatide (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V | Commission completed |